The Gi-Guard treatment is progressing within APVMA process and...

The Gi-Guard treatment is progressing within APVMA process and discretion. In the meantime potential distributors are now courting BPO for local and Oceania distribution rights.
The main area of concern I gather, is over a potentially competing product that's outside the Bioeffective agreement [read RE-GEN] - its probably as much as a shareholder conflict concern as well as a show of dissatisfaction with the resource divergence that SLA considered could have gone into BIO-A husbandry R&D.

Given the size of the conflict in in the context of it all - I'm think it was overplayed, I think a reality check was taken and its an agree to disagree - playground type spat. After all, but the big V dominates the SLA board and his frustration with progress back in Russia may have been a stimulus to the action. But BPO is not V's company and its board must decide the best track for BPO shareholders. The Malaysian connection is also taking much longer than anticipated too - such is the ground of BIO R&D.
I hold both and see great potential for both.